Advances in Cancer Immunotherapy™:
A Focus on Lung Cancer

Tuesday, April 5, 2022
12-4 p.m. EDT
Live via Zoom Webinar

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of clinical implementation of immunotherapy for lung cancer.

Organizers:

Anne Chiang, MD, PhD – Yale School of Medicine
Marianne Davies, NP, DNP, MSN, BSN – Yale University, Yale School of Nursing
Roy S. Herbst, MD, PhD – Yale Cancer Center, Yale School of Medicine, Smilow Cancer Hospital Center

Registration:
Registration for this program will be open until 12 p.m. EDT on April 5, 2022.

Program Agenda

12–12:10 p.m.	Welcome Anne Chiang, MD, PhD – Yale School of Medicine Marianne Davies, NP, DNP, MSN, BSN –Yale University, Yale School of Nursing Roy S. Herbst, MD, PhD – Yale Cancer Center, Yale School of Medicine, Smilow Cancer Hospital
12:10–12:35 p.m.	“Coke or Pepsi”: how to decide on first-line treatment for metastatic NSCLC without driver mutations? Hossein Borghaei, DO, MS – Fox Chase Cancer Center
12:35–1 p.m.	New Directions and Immunotherapy resistance: how to treat patients progressing on therapy Mark Awad, MD, PhD – Dana-Farber Cancer Institute
1–1:25 p.m.	Targeted therapies: what are new approaches for NSCLC patients with driver mutations? Sarah B. Goldberg, MD, MPH – Yale School of Medicine
1:25–1:50 p.m.	New Directions and SCLC Treatment Anne Chiang, MD, PhD – Yale School of Medicine
1:50-2:05 p.m.	Break
2:05–2:20 p.m.	Cancer Immunotherapy In Practice: is the benefit worth the risk? Marianne Davies, NP, DNP, MSN, BSN – Yale University, Yale School of Nursing
2:20–2:35 p.m.	Immunotherapy and Radiation: Considerations on Outcomes and Toxicity Henry S. Park, MD, MPH – Yale School of Medicine
2:35-2:50 p.m.	Immunotherapy Clinical Trials: Highlights and Updates Scott N. Gettinger, MD – Yale School of Medicine
2:50–4 p.m.	Faculty Case Study Panel Mark Awad, MD, PhD – Dana-Farber Cancer Institute Hossein Borghaei, DO, MS – Fox Chase Cancer Center Scott N. Gettinger, MD – Yale School of Medicine Sarah B. Goldberg, MD, MPH – Yale School of Medicine Henry S. Park, MD, MPH – Yale School of Medicine

Case Study Submission Information:
To submit closed/past case studies for live expert panel feedback, please indicate your interest in the checkbox in program registration and SITC staff will follow up with you through email with further instruction.

Program Learning Objectives

Summarize recent updates in cancer immunotherapy for lung cancer and toxicity management for key disease states.
Implement cancer immunotherapy for lung cancer into clinical practice appropriately.
Describe management approaches for difficult or refractory immune-related adverse events.
Describe the use of biomarkers to select appropriate cancer immunotherapies for lung cancer patients.

Target Audience
The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute of Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

Avoid Fraudulent ACI Registration Websites

Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org.

If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.

Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact SITC Staff prior to the live event at (414) 271-2456 or via email education@sitcancer.org.

The ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Postgraduate Institute for Medicine SITC Logo

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc. (as of 1/19/2022)

The 2021-2022 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the Association of Community Cancer Centers, Advances Practitioner Society for Hematology and Oncology, and Hematology/Oncology Pharmacy Association.